Li-Xuan Qin, PhD

Associate Attending Biostatistician
Li-Xuan Qin


University of Washington

Current Research Interests

Dr. Qin develops benchmark data, analytic methods, and computational tools for enabling reproducible statistical translations of high-dimensional biomedical data. With wet-lab colleagues, she has designed and collected unique benchmark datasets to study the issue of data normalization for microarrays and sequencing. She has built simulation algorithms and software tools to decipher the interactions between data normalization and subsequent analysis (such as sample classification and survival prediction) and is developing statistical methods to facilitate evidence-based practice of data normalization. Her research program in reproducible statistical learning for cancer omics data has been supported by multiple completed and ongoing grants awarded by the NIH.

Dr. Qin collaborates with multidisciplinary investigators engaged in research on soft tissue sarcoma and colorectal cancer at MSK, for design and analysis of retrospective and prospective studies. She serves as Co-Director of the Biostatistics and Bioinformatics Core of the MSK Soft Tissue Sarcoma SPORE. Over the years she has also worked with investigators studying the molecular basis of other cancer types such as breast, ovarian, pancreatic, and pediatric cancer.

Dr. Qin is a member of MSK Research Council, reviewing investigator-initiated and industry-sponsored protocols for scientific merit and priority. At the national level, she serves as Editorial Board Member for Journal of Clinical Oncology, Treasurer for Section on Statistics in Genomics and Genetics of American Statistical Association, and Regular Member for the NIH BMRD Study Section.


Selected peer-reviewed publications:

  1. Qin LX, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, Satagopan JM, Begg CB, Levine DA. Blocking and randomization to improve molecular biomarker discovery. Clinical Cancer Research 2014, 20:3371-3378.
  2. Qin LX, Huang HC, Begg CB. Cautionary note on using cross-validation for molecular classification. Journal of Clinical Oncology 2016, 34:3931-3938.
  3. Qin LX, Zou J, Shi J, Lee A, Mihailovic A, Farazi TA, Tuschl T, Singer S. Statistical assessment of depth normalization for small RNA sequencing. Journal of Clinical Oncology Clinical Cancer Informatics 2020, 4:567-582
  4. Ni A, Qin LX. Performance evaluation of transcriptomics data normalization for survival outcome prediction. Briefings in Bioinformatics 2021, 22:bbab257.
  5. Düren Y, Lederer J, Qin LX. Depth normalization of small RNA sequencing: using data and biology to select a suitable method. Nucleic Acids Research 2022, Online ahead of print.

View a full listing of Li-Xuan Qin’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Li-Xuan Qin discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures